Interim Report Q2 – April – June, 2023 Redsense Medical AB (publ)
APRIL – JUNE 2023 · Net sales amounted to kSEK 4,831 (1,927), an increase of 151%. · Operating loss, EBIT amounted to kSEK 3,045 (2,428). · Result after tax amounted to kSEK -2,966 (-2,137). · Earnings per share were SEK -0.21 (-0.15). SIGNIFICANT EVENTS DURING THE PERIOD · On April 28, Redsense announced that Redsense and FDA held a Pre-Submission Meeting in preparation for the 510(k) Premarket Submission of the Redsense Clamp. · On May 8, Redsense announced that the Home Dialysis Risk Prevention Act was introduced by the US House of Representatives. · On June